Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 2,174 shares of the business's stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total value of $65,480.88. Following the sale, the chief operating officer now owns 176,206 shares of the company's stock, valued at approximately $5,307,324.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Patrick John Finn also recently made the following trade(s):
- On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $16,108.08.
Twist Bioscience Trading Up 1.1 %
NASDAQ TWST opened at $31.08 on Friday. Twist Bioscience Co. has a 12 month low of $11.46 and a 12 month high of $43.21. The stock has a 50-day simple moving average of $34.97 and a 200 day simple moving average of $30.32.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. Twist Bioscience's revenue was up 31.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.74) earnings per share. As a group, equities analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current year.
Wall Street Analyst Weigh In
Is Tesla going out of business?
From DTI | Ad
Goldman Sachs estimates that this new “Future Fuel” will unleash an $11.7 trillion wave of wealth over the coming decade.
That’s 10 TIMES BIGGER than the electric vehicle market.
Click here for the full story
A number of equities research analysts have recently weighed in on the company. Scotiabank boosted their target price on Twist Bioscience from $30.00 to $43.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 5th. The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and upped their price objective for the company from $25.00 to $45.00 in a report on Wednesday, January 17th. Finally, Barclays dropped their price objective on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a report on Wednesday, April 10th.
View Our Latest Report on Twist Bioscience
Institutional Investors Weigh In On Twist Bioscience
A number of hedge funds have recently modified their holdings of the business. D.A. Davidson & CO. raised its position in shares of Twist Bioscience by 3.4% during the fourth quarter. D.A. Davidson & CO. now owns 16,774 shares of the company's stock worth $618,000 after purchasing an additional 554 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Twist Bioscience by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company's stock worth $30,000 after purchasing an additional 721 shares during the period. Teacher Retirement System of Texas raised its position in shares of Twist Bioscience by 5.1% during the third quarter. Teacher Retirement System of Texas now owns 16,206 shares of the company's stock worth $328,000 after purchasing an additional 790 shares during the period. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience during the fourth quarter worth about $30,000. Finally, Harbor Capital Advisors Inc. grew its holdings in shares of Twist Bioscience by 4.3% during the third quarter. Harbor Capital Advisors Inc. now owns 25,897 shares of the company's stock worth $525,000 after buying an additional 1,062 shares in the last quarter.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
